Renal Impairment Is Associated With Coronary Heart Disease in HIV-Positive Men

REFERENCES

• Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29–35.
   PubMedGoogle Scholar
• Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection ? J Acquir Immune Defic Syndr 2002;30(5):471–477.
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metabol. 2007;92(7): 2506–2512.
   PubMed Web of Science ®Google Scholar
• Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33(4):506–512.
   PubMed Web of Science ®Google Scholar
• Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009;50(1):54–64.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS. 2010;24(6):789–802.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12): 1788–1795.
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203(4):452–463.
   PubMed Web of Science ®Google Scholar
• Solages A, Vita JA, Thornton DJ, et al. Endothelial func-tion in HIV-infected persons. Clin Infect Dis. 2006;42(9): 1325–1332.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23(14):1841–1849.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059–1067.
   PubMed Web of Science ®Google Scholar
• Kingsley LA, Cuervo-Rojas J, Munoz A, et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS. 2008;22(13):1589–1599.
   PubMed Web of Science ®Google Scholar
• Lo J, Abbara S, Shturman L, Soni A, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2):243–253.
   PubMed Web of Science ®Google Scholar
• Baker JV, Neuhaus J, Duprez D, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011;56(1):36–43.
   PubMed Web of Science ®Google Scholar
• Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23(8):929–939.
   PubMed Web of Science ®Google Scholar
• Baker JV, Henry WK, Patel P, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis. 2011;53(8):826–835.
   PubMed Web of Science ®Google Scholar
• Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS. 2010;24(12):1897–1905.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected anti-retroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coil CardioL 2008;52(7):569–576.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–2296.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17)1 723–1735.
   Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417–1426.
   PubMed Web of Science ®Google Scholar
• Post FA, Holt SG. Recent developments in HIV and the kidney. Curr Opin Infect Dis. 2009;22(1):43–48.
   PubMed Web of Science ®Google Scholar
• Choi Al, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121(5):651–658.
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Estrada V, Gomez-Garre D, et al. Incipient renal impairment as a predictor of subclinical atherosclerosis in HIV-infected patients. J Acquir Immune Defic Syndr 2012;59(2)1 41–148.
   Web of Science ®Google Scholar
• Jotwani V, Scherzer R, Choi A, et al. Reduced kidney function and preclinical atherosclerosis in HIV-infected individuals: the study of fat redistribution and metabolic change in HIV infection (FRAM). Am J Nephrol. 2011;33(5):453–460.
   PubMed Web of Science ®Google Scholar
• George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24(3):387–394.
   PubMed Web of Science ®Google Scholar
• Lifson AR, Belloso WH, Davey RT, et al. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials. 2010;11(4):205–219.
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Nephrol Dial Transplant. 2011;27(6):2291–2297.
   PubMed Web of Science ®Google Scholar
• Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, et al. Cardiovascular risk evaluation and antiretro-viral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin PracL 2010;64(9)1252–1259.
   Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Naftalin C, Cheserem E, et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010;24(14):2239–2244.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10(6):329–336.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, Lkizler TA. Hemodialysis. N Engl J Med. 2010;363(19)1 833–1845.
   Web of Science ®Google Scholar
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17–24.
   PubMed Web of Science ®Google Scholar
• Choi Al, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25(10)1289–1298.
   Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Gotta L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort C04. Arch Intern Med. 2010;170(14)1228–1238.
   Web of Science ®Google Scholar
• Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51(4):435–447.
   PubMed Web of Science ®Google Scholar
• Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010;55:615–619.
   PubMed Web of Science ®Google Scholar
• Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84–91.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25(16): 1993–2004.
   PubMed Web of Science ®Google Scholar
• Post FA, Campbell U. Abacavir and increased risk of myocardial infarction. Lancet. 2008;372(9641):803; author reply 4–5.
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130–1139.
   PubMed Web of Science ®Google Scholar